MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 4, 2005; DOI: 10.1124/mol.105.011940


0026-895X/05/6706-2007-2015$20.00
Mol Pharmacol 67:2007-2015, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.011940v1
67/6/2007    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gotti, C.
Right arrow Articles by Whiteaker, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gotti, C.
Right arrow Articles by Whiteaker, P.

Expression of Nigrostriatal {alpha}6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by {beta}3 Subunit Gene Deletion

Cecilia Gotti, Milena Moretti, Francesco Clementi, Loredana Riganti, J. Michael McIntosh, Allan C. Collins, Michael J. Marks, and Paul Whiteaker

Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Cellular and Molecular Pharmacology, Department of Medical Pharmacology and Center of Excellence on Neurodegenerative Diseases, University of Milan, Milan, Italy (C.G., M.M., F.C., L.R.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (M.J.M., A.C.C., P.W.); and Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado (J.M.M.)

mRNAs for the neuronal nicotinic acetylcholine receptor (nAChR) {alpha}6 and {beta}3 subunits are abundantly expressed and colocalized in dopaminergic cells of the substantia nigra and ventral tegmental area. Studies using subunit-null mutant mice have shown that {alpha}6- or {beta}3-dependent nAChRs bind {alpha}-conotoxin MII ({alpha}-CtxMII) with high affinity and modulate striatal dopamine release. This study explores the effects of {beta}3 subunit-null mutation on striatal and midbrain nAChR expression, composition, and pharmacology. Ligand binding and immunoprecipitation experiments using subunit-specific antibodies indicated that {beta}3-null mutation selectively reduced striatal {alpha}6* nAChR expression by 76% versus {beta}3+/+ control. Parallel experiments showed a smaller reduction in both midbrain {alpha}3* and {alpha}6* nAChRs (34 and 42% versus {beta}3+/+ control, respectively). Sedimentation coefficient determinations indicated that residual {alpha}6* nAChRs in {beta}3–/– striatum were pentameric, like their wild-type counterparts. Immunoprecipitation experiments on immunopurified {beta}3* nAChRs demonstrated that almost all wild-type striatal {beta}3* nAChRs also contain {alpha}4, {alpha}6, and {beta}2 subunits, although a small population of non-{beta}3 {alpha}6* nAChRs is also expressed. {beta}3 subunit incorporation seemed to increase {alpha}4 participation in {alpha}6{beta}2* complexes. 125I-Epibatidine competition binding studies showed that the {alpha}-CtxMII affinity of {alpha}6* nAChRs from the striata of {beta}3–/– mice was similar to those isolated from {beta}3+/+ animals. Together, the results of these experiments show that the {beta}3 subunit is important for the correct assembly, stability and/or transport of {alpha}6* nAChRs in dopaminergic neurons and influences their subunit composition. However, {beta}3 subunit expression is not essential for the expression of {alpha}6*, high-affinity {alpha}-CtxMII binding nAChRs.


Received February 9, 2005; accepted March 4, 2005

Address correspondence to: Dr. Cecilia Gotti, Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Section of Cellular and Molecular Pharmacology Center, Department of Medical Pharmacology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy. E-mail: c.gotti{at}in.cnr.it




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. P. Dwoskin, T. E. Wooters, S. P. Sumithran, K. B. Siripurapu, B. M. Joyce, P. R. Lockman, V. K. Manda, J. T. Ayers, Z. Zhang, A. G. Deaciuc, et al.
N,N'-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-Evoked Dopamine Release and Hyperactivity
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 563 - 576.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Whiteaker, M. J. Marks, S. Christensen, C. Dowell, A. C. Collins, and J. M. McIntosh
Synthesis and Characterization of 125I-{alpha}-Conotoxin ArIB[V11L;V16A], a Selective {alpha}7 Nicotinic Acetylcholine Receptor Antagonist
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 910 - 919.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Gotti, M. Moretti, N. M. Meinerz, F. Clementi, A. Gaimarri, A. C. Collins, and M. J. Marks
Partial Deletion of the Nicotinic Cholinergic Receptor {alpha}4 or {beta}2 Subunit Genes Changes the Acetylcholine Sensitivity of Receptor-Mediated 86Rb+ Efflux in Cortex and Thalamus and Alters Relative Expression of {alpha}4 and {beta}2 Subunits
Mol. Pharmacol., June 1, 2008; 73(6): 1796 - 1807.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. S. Zeiger, B. C. Haberstick, I. Schlaepfer, A. C. Collins, R. P. Corley, T. J. Crowley, J. K. Hewitt, C. J. Hopfer, J. Lessem, M. B. McQueen, et al.
The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco
Hum. Mol. Genet., March 1, 2008; 17(5): 724 - 734.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. M. Drenan, R. Nashmi, P. Imoukhuede, H. Just, S. McKinney, and H. A. Lester
Subcellular Trafficking, Pentameric Assembly, and Subunit Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors Containing Fluorescently Labeled {alpha}6 and 3 Subunits
Mol. Pharmacol., January 1, 2008; 73(1): 27 - 41.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. Nashmi, C. Xiao, P. Deshpande, S. McKinney, S. R. Grady, P. Whiteaker, Q. Huang, T. McClure-Begley, J. M. Lindstrom, C. Labarca, et al.
Chronic Nicotine Cell Specifically Upregulates Functional {alpha}4* Nicotinic Receptors: Basis for Both Tolerance in Midbrain and Enhanced Long-Term Potentiation in Perforant Path
J. Neurosci., August 1, 2007; 27(31): 8202 - 8218.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. C. Perry, D. Mao, A. B. Gold, J. M. McIntosh, J. C. Pezzullo, and K. J. Kellar
Chronic Nicotine Differentially Regulates {alpha}6- and beta3-Containing Nicotinic Cholinergic Receptors in Rat Brain
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 306 - 315.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
O. Salminen, J. A. Drapeau, J. M. McIntosh, A. C. Collins, M. J. Marks, and S. R. Grady
Pharmacology of {alpha}-Conotoxin MII-Sensitive Subtypes of Nicotinic Acetylcholine Receptors Isolated by Breeding of Null Mutant Mice
Mol. Pharmacol., June 1, 2007; 71(6): 1563 - 1571.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik
Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Tumkosit, A. Kuryatov, J. Luo, and J. Lindstrom
beta3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic {alpha}6* Nicotinic Acetylcholine Receptors Expressed in Transfected Cell Lines
Mol. Pharmacol., October 1, 2006; 70(4): 1358 - 1368.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. Azam and J. M. McIntosh
Characterization of Nicotinic Acetylcholine Receptors That Modulate Nicotine-Evoked [3H]Norepinephrine Release from Mouse Hippocampal Synaptosomes
Mol. Pharmacol., September 1, 2006; 70(3): 967 - 976.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Quik and J. M. McIntosh
Striatal {alpha}6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 481 - 489.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. M. Marritt, B. C. Cox, R. P. Yasuda, J. M. McIntosh, Y. Xiao, B. B. Wolfe, and K. J. Kellar
Nicotinic Cholinergic Receptors in the Rat Retina: Simple and Mixed Heteromeric Subtypes
Mol. Pharmacol., December 1, 2005; 68(6): 1656 - 1668.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Gotti, M. Moretti, A. Zanardi, A. Gaimarri, N. Champtiaux, J.-P. Changeux, P. Whiteaker, M. J. Marks, F. Clementi, and M. Zoli
Heterogeneity and Selective Targeting of Neuronal Nicotinic Acetylcholine Receptor (nAChR) Subtypes Expressed on Retinal Afferents of the Superior Colliculus and Lateral Geniculate Nucleus: Identification of a New Native nAChR Subtype {alpha}3{beta}2({alpha}5 or {beta}3) Enriched in Retinocollicular Afferents
Mol. Pharmacol., October 1, 2005; 68(4): 1162 - 1171.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. McIntosh, P. V. Plazas, M. Watkins, M. E. Gomez-Casati, B. M. Olivera, and A. B. Elgoyhen
A Novel {alpha}-Conotoxin, PeIA, Cloned from Conus pergrandis, Discriminates between Rat {alpha}9{alpha}10 and {alpha}7 Nicotinic Cholinergic Receptors
J. Biol. Chem., August 26, 2005; 280(34): 30107 - 30112.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics